GENNEX LABORATORIES
|
The Current P/E Ratio of GENNEX LABORATORIES is 12.29.
| Share Price | ₹10.6 | Jun 08,2026 |
| Market Cap | ₹257.8 Cr | |
| Earnings-TTM | ₹21.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 12.29x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of GENNEX LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹257.8 Cr] as on Jun 08,2026
(/) Earnings [ ₹21.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 12.29x ]
Thus, for GENNEX LABORATORIES , the investors are currently willing to pay 12.29 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GENNEX LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GENNEX LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of GENNEX LABORATORIES
PE Ratio Performance Analysis for GENNEX LABORATORIES
- GENNEX LABORATORIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 19.31x.
- GENNEX LABORATORIES 's operated at median p/e ratio of 16x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GENNEX LABORATORIES 's p/e ratio peaked in Mar2024 at 31.6x.
- GENNEX LABORATORIES 's p/e ratio hit its five-year low in Mar2021 of 11.69x.
How does GENNEX LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| GENNEX LABORATORIES | 20.98 | 12.29 | 257.8 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 37.11 | 429,145.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 67.36 | 172,989.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 69.84 | 149,322.0 |
| CIPLA LTD | 3,869.79 | 28.98 | 112,149.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 25.69 | 106,483.0 |
| MANKIND PHARMA LTD | 1,926.41 | 50.55 | 97,382.6 |
| LUPIN LTD | 5,355.47 | 19.23 | 102,996.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 21.77 | 109,423.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 23.86 | 83,536.2 |
| LAURUS LABS LTD | 889.85 | 85.27 | 75,880.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GENNEX LABORATORIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 12.29x |
| Max industry PE | 85.27x |
| Median industry PE | 28.98x |
| Average industry PE | 40.18x |
You may also like the below Video Courses